June 23, 2026 - 20:30

The recent rally in software stocks is hitting a critical juncture, with two of the sector's biggest names now under the microscope. Palantir Technologies and Salesforce are both struggling to reclaim key price levels, and until they do, the broader software rebound remains unconfirmed. Investors are watching these two names closely because their performance often signals the health of the entire enterprise tech space.
Palantir, known for its data analytics platforms, has seen its stock surge on artificial intelligence hype, but it has yet to break through a stubborn resistance zone that has capped gains for months. Salesforce, the customer relationship management giant, faces a similar wall. Despite cost-cutting measures and a push into AI tools, its shares have failed to hold above a crucial moving average that bulls need to see cleared.
The problem is not just technical. Both companies are dealing with a cautious spending environment. Businesses are still scrutinizing every software contract, prioritizing tools that deliver immediate returns over long-term bets. Until Palantir and Salesforce can show sustained momentum above their respective ceilings, the narrative of a full software recovery is just speculation. For now, the verdict is still out, and the sector's fate hangs on whether these two leaders can finally break through.
November 6, 2026 - 03:46
Hyperliquid Strategies Reports Strong Q1 EarningsHyperliquid Strategies is taking steps to become a futures commission merchant for U.S. clients. In its latest earnings call, the company announced a remarkable $621 million in net income for the...
November 5, 2026 - 18:54
Charleston County Leaders to Consider $3 Million for Land PreservationCharleston County leaders will be meeting Thursday to discuss a request for over $3 million in Greenbelt funding, which would go toward preserving and protecting land in Hollywood. This funding is...
November 5, 2026 - 18:37
Agenus Aims for Phase 3 Trial in Colon Cancer as Funding Depends on EnrollmentAgenus plans to start patient enrollment in the coming months for a Phase 3 trial of its investigational immunotherapy combination BOT/BAL aimed at treating early-stage colon cancer. During a...
November 4, 2026 - 20:16
Burford Capital Shares Financial Performance for Third Quarter and Year-to-Date 2026Burford Capital Limited has released its unaudited financial results for the third quarter and year-to-date ending September 30, 2026. The firm, known for its focus on finance and asset management...